F. Gomes, N. Gilding, V. Tan, K. Christoforou, J. Rule, A. Aziez, Adam Januszewski, A. Minchom
{"title":"101 在COVID-19大流行之前和期间,对培美曲塞一线维持治疗(1LM)和免疫疗法(IO)对缺乏靶向突变的非鳞状(NSQ)晚期/转移性非小细胞肺癌(a/mNSCLC)的影响的真实世界分析","authors":"F. Gomes, N. Gilding, V. Tan, K. Christoforou, J. Rule, A. Aziez, Adam Januszewski, A. Minchom","doi":"10.1016/j.lungcan.2024.107662","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":507097,"journal":{"name":"Lung cancer","volume":"11 9","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"101 Real-world analysis of the impact of pemetrexed in first-line maintenance (1LM) with immunotherapy (IO) for non-squamous (NSQ) advanced/metastatic non-small cell lung cancer (a/mNSCLC) lacking targetable mutations, prior to and during the COVID-19 pandemic\",\"authors\":\"F. Gomes, N. Gilding, V. Tan, K. Christoforou, J. Rule, A. Aziez, Adam Januszewski, A. Minchom\",\"doi\":\"10.1016/j.lungcan.2024.107662\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":507097,\"journal\":{\"name\":\"Lung cancer\",\"volume\":\"11 9\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Lung cancer\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1016/j.lungcan.2024.107662\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Lung cancer","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.lungcan.2024.107662","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
101 Real-world analysis of the impact of pemetrexed in first-line maintenance (1LM) with immunotherapy (IO) for non-squamous (NSQ) advanced/metastatic non-small cell lung cancer (a/mNSCLC) lacking targetable mutations, prior to and during the COVID-19 pandemic